<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TOLNAFTATE</span><br/>(tole-naf'tate)<br/><span class="topboxtradename">Aftate, </span><span class="topboxtradename">Pitrex <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Tinactin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antifungal antibiotic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1% cream, solution, gel, powder, spray</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic topical antifungal agent. Action mechanism not clear, but has been shown that tolnaftate distorts hyphae and stunts
         mycelial growth on susceptible fungi.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Fungistatic or fungicidal to <i>Microsporum,</i> specifically <i>M. gypseum, M. canis, M. audouinii, M. japonicum, Trichophyton, T. rubrum, T. schoenleinii, T. tonsurans,</i> and <i>Epidermophyton floccosum,</i> but ineffective against <i>Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus,</i> bacteria, protozoa, and viruses.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (body ringworm); also tinea capitis and tinea unguium
         if infection is superficial, plantar or palmar lesions adjunctively with keratolytic agents, and tinea versicolor (caused
         by <i>Malassezia furfur</i>).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Skin irritations prior to therapy, nail and scalp infections. Safety during pregnancy (category C), lactation, or by children
         
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Excoriated skin.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Tinea Infestations</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">Topical</span> Apply 0.51 cm (<small>1/4</small>½ in) of cream or 3 drops of solution b.i.d. in morning and evening; powder may
               be used prophylactically in normally moist areas<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Cleanse site thoroughly with water and dry completely before applying. Massage thin layer gently into skin. Make sure area
            is not wet from excess drug after application.
         </li>
<li>Shake aerosol powder container well before use.</li>
<li>
            				Note: Cream and powder are not recommended for nail or scalp infection.
            			
         </li>
<li>Use liquids (solutions) for scalp infection or to treat hairy areas.</li>
<li>Store cream, gel, powder, and topical solution in light-resistant containers at 15°30° C (59°86°
            F); store aerosol container at 2°30° C (38°86° F). Avoid freezing and exposure to light.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Skin:</span> Local irritation, stinging of skin from aerosol formulation. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1>Not studied. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Expect relief from pruritus, soreness, and burning within 2472 h after start of treatment.</li>
<li>Continue treatment for 23 wk after disappearance of all symptoms to prevent recurrence.</li>
<li>Return to physician for reevaluation in absence of improvement within 4 wk.</li>
<li>
            							Note: If skin has thickened as a result of the infection, desired clinical response may be delayed for 46 wk.
            						
         </li>
<li>Avoid contact with eyes of all drug forms.</li>
<li>Place container in warm water to liquefy contents if solution solidifies. Potency is unaffected.</li>
<li>Do not breast feed while using this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>